Novartis 2026 Guidance a Bit Soft on Earnings -- Market Talk
Dow Jones
Feb 04
0803 GMT - Novartis's guidance for this year is a bit soft on core earnings before interest and taxes, Morgan Stanley analysts Thibault Boutherin and Sarita Kapila write in a research note. The Swiss drugmaker also reported some minor delays in trial results that could cause shares to underperform, they say. The company's forecast of a decline in core EBIT "reflects the impact of [loss of patent exclusivity] and expected margin dilution from the Avidity acquisition," the analysts add. (william.gray@wsj.com)
(END) Dow Jones Newswires
February 04, 2026 03:04 ET (08:04 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.